SK282744B6 - Kapsula opuzdrujúca bunku produkujúcu cytochróm P450, farmaceutický prostriedok a súprava s jej obsahom, a jej použitie - Google Patents

Kapsula opuzdrujúca bunku produkujúcu cytochróm P450, farmaceutický prostriedok a súprava s jej obsahom, a jej použitie Download PDF

Info

Publication number
SK282744B6
SK282744B6 SK1323-98A SK132398A SK282744B6 SK 282744 B6 SK282744 B6 SK 282744B6 SK 132398 A SK132398 A SK 132398A SK 282744 B6 SK282744 B6 SK 282744B6
Authority
SK
Slovakia
Prior art keywords
cytochrome
cells
prodrug
capsule
vector
Prior art date
Application number
SK1323-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK132398A3 (en
Inventor
Walter H. G�Nzburg
Peter Karle
Robert Michael Saller
Original Assignee
Bavarian Nordic Research Institute A/S
GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8092560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282744(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic Research Institute A/S, GSF-Forschungszentrum f�r Umwelt und Gesundheit GmbH filed Critical Bavarian Nordic Research Institute A/S
Publication of SK132398A3 publication Critical patent/SK132398A3/sk
Publication of SK282744B6 publication Critical patent/SK282744B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C12N9/0079—Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK1323-98A 1996-03-27 1997-03-27 Kapsula opuzdrujúca bunku produkujúcu cytochróm P450, farmaceutický prostriedok a súprava s jej obsahom, a jej použitie SK282744B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK35296 1996-03-27
PCT/EP1997/001585 WO1997035994A2 (en) 1996-03-27 1997-03-27 Cytochrome p450 transducing retroviral vectors

Publications (2)

Publication Number Publication Date
SK132398A3 SK132398A3 (en) 1999-04-13
SK282744B6 true SK282744B6 (sk) 2002-12-03

Family

ID=8092560

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1323-98A SK282744B6 (sk) 1996-03-27 1997-03-27 Kapsula opuzdrujúca bunku produkujúcu cytochróm P450, farmaceutický prostriedok a súprava s jej obsahom, a jej použitie

Country Status (19)

Country Link
US (1) US6893634B1 (hu)
EP (1) EP0892852B1 (hu)
JP (1) JP4229982B2 (hu)
AT (1) ATE309383T1 (hu)
AU (1) AU713382B2 (hu)
CA (1) CA2250173A1 (hu)
CZ (1) CZ288074B6 (hu)
DE (1) DE69730595D1 (hu)
DK (1) DK0892852T3 (hu)
ES (1) ES2253775T3 (hu)
HU (1) HU221349B1 (hu)
IL (1) IL125795A0 (hu)
NO (1) NO325392B1 (hu)
NZ (1) NZ331765A (hu)
PL (1) PL188323B1 (hu)
RU (2) RU2223788C2 (hu)
SI (1) SI0892852T1 (hu)
SK (1) SK282744B6 (hu)
WO (1) WO1997035994A2 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
EP1115871A2 (en) * 1998-09-21 2001-07-18 Transgene S.A. Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
GB0400443D0 (en) 2004-01-09 2004-02-11 Oxford Biomedica Ltd Cascade
AU1869900A (en) * 1999-01-04 2000-07-24 Ml Laboratories Plc P450/acetaminophen GDEPT for cancer treatment
GB9900009D0 (en) * 1999-01-04 1999-02-24 Ml Lab Plc Gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
EP1427836A2 (en) * 2001-09-21 2004-06-16 Oxford Biomedica (UK) Limited Pseudotyped retroviral vector system
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
MX2015006813A (es) * 2015-05-29 2016-11-28 Univ Nac Autónoma De México Nanoparticulas biocataliticas cyp-p22 con actividad citocromo p450 para la activacion de profarmacos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927089T2 (de) 1988-05-17 1997-04-03 Sloan Kettering Inst Cancer Retroviraler vektor
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
JP4037446B2 (ja) 1994-09-02 2008-01-23 ゲーエスエフ − フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 非自己不活化性の発現標的化レトロウイルスベクタ
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
ES2174103T3 (es) * 1995-09-06 2002-11-01 Austrian Nordic Biotherapeutic Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы

Also Published As

Publication number Publication date
NO984540L (no) 1998-09-28
EP0892852B1 (en) 2005-11-09
PL188323B1 (pl) 2005-01-31
PL329071A1 (en) 1999-03-15
NO984540D0 (no) 1998-09-28
CZ305098A3 (cs) 1999-01-13
HUP9904116A2 (hu) 2000-04-28
RU2185821C2 (ru) 2002-07-27
SI0892852T1 (sl) 2006-04-30
NZ331765A (en) 2000-02-28
ES2253775T3 (es) 2006-06-01
WO1997035994A2 (en) 1997-10-02
DE69730595D1 (de) 2004-10-14
HU221349B1 (en) 2002-09-28
CZ288074B6 (cs) 2001-04-11
JP2000509249A (ja) 2000-07-25
JP4229982B2 (ja) 2009-02-25
NO325392B1 (no) 2008-04-21
HUP9904116A3 (en) 2001-01-29
SK132398A3 (en) 1999-04-13
WO1997035994A3 (en) 1997-11-20
EP0892852A2 (en) 1999-01-27
US6893634B1 (en) 2005-05-17
AU713382B2 (en) 1999-12-02
ATE309383T1 (de) 2005-11-15
RU2223788C2 (ru) 2004-02-20
DK0892852T3 (da) 2006-03-06
AU2382797A (en) 1997-10-17
IL125795A0 (en) 1999-04-11
CA2250173A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
EP0702084B1 (en) Recombinant retroviruses
Vile et al. Retroviruses as vectors
US6117681A (en) Pseudotyped retroviral particles
US20020051763A1 (en) Host-vector system which can be used in gene therapy
JP4848348B2 (ja) ウイルス粒子産生カプセル化細胞
RU2185821C2 (ru) Трансдуцирующие цитохром р450 ретровирусные векторы
US20140170709A1 (en) Vector for gene therapy
EP0848757B1 (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
EP1115879B1 (en) Retroviral particles protected against complement mediated destruction
EP0817860B1 (en) Pseudotyped retroviral particles
US6540995B1 (en) Encapsulated cells producing cytochrome P450
Searle et al. Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene
JPH11503916A (ja) 高力価組換えレトロウイルス調製物による細胞の高効率エクスビボ形質導入
US20040115800A1 (en) Selectable marker for genetically engineered cells and tissues
Fassati et al. Retroviral vectors
Burt et al. Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes
Takebe et al. MDR-1 8.3. 3 Cytidine Deaminase 8.3. 4 Aldehyde Dehydrogenase Class 1 Dihydrofolate Reductase
EP0859854A1 (en) Retroviral vectors carrying senescent cell derived inhibitors 1 (sdi-1) or antisense sdi-1 nucleotide sequences

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110327